Biological Predictors of Treatment Response in Adult Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review.
adult
attention-deficit/hyperactivity disorder (ADHD)
markers
outcome
treatment response
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
20 Oct 2022
20 Oct 2022
Historique:
received:
29
08
2022
revised:
12
10
2022
accepted:
17
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent condition with onset in childhood and in many cases persisting into adulthood. Even though an increasing number of studies have investigated the efficacy of pharmacotherapy in the management of adult ADHD, few authors have tried to identify the biological predictors of treatment response. To summarize the available data about the biological markers of treatment response in adults affected by ADHD. A search on the main biomedical and psychological archives (PubMed, Embase, Scopus, and PsycINFO) was performed. Manuscripts in English, published up to May 2022 and having the biological predictors of treatment response in adults with ADHD as their main topic, were included. A total of 3855 articles was screened. Twenty-two articles were finally included. Most of the manuscripts studied neuroimaging and electrophysiological factors as potential predictors of treatment response in adult ADHD patients. No reliable markers were identified until now. Promising findings on this topic regard genetic polymorphisms in snap receptor (SNARE) proteins and default mode network-striatum connectivity. Even though some biological markers seem promising for the prediction of treatment response in adults affected by ADHD, further studies are needed to confirm the available data in the context of precision medicine.
Sections du résumé
BACKGROUND
BACKGROUND
Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent condition with onset in childhood and in many cases persisting into adulthood. Even though an increasing number of studies have investigated the efficacy of pharmacotherapy in the management of adult ADHD, few authors have tried to identify the biological predictors of treatment response.
OBJECTIVES
OBJECTIVE
To summarize the available data about the biological markers of treatment response in adults affected by ADHD.
METHODS
METHODS
A search on the main biomedical and psychological archives (PubMed, Embase, Scopus, and PsycINFO) was performed. Manuscripts in English, published up to May 2022 and having the biological predictors of treatment response in adults with ADHD as their main topic, were included.
RESULTS
RESULTS
A total of 3855 articles was screened. Twenty-two articles were finally included. Most of the manuscripts studied neuroimaging and electrophysiological factors as potential predictors of treatment response in adult ADHD patients. No reliable markers were identified until now. Promising findings on this topic regard genetic polymorphisms in snap receptor (SNARE) proteins and default mode network-striatum connectivity.
CONCLUSIONS
CONCLUSIONS
Even though some biological markers seem promising for the prediction of treatment response in adults affected by ADHD, further studies are needed to confirm the available data in the context of precision medicine.
Identifiants
pubmed: 36294881
pii: jpm12101742
doi: 10.3390/jpm12101742
pmc: PMC9605680
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):1003-1019.e20
pubmed: 23021477
Sci Rep. 2020 Dec 28;10(1):22388
pubmed: 33372183
Arch Gen Psychiatry. 2008 Jan;65(1):102-14
pubmed: 18180434
Hum Brain Mapp. 2017 Oct;38(10):4850-4864
pubmed: 28657141
Schizophr Res. 2020 May;219:77-83
pubmed: 31053491
Psychiatr Res Clin Pract. 2021 May 19;3(4):146-152
pubmed: 36101656
CNS Drugs. 2016 Apr;30(4):317-34
pubmed: 27055440
Front Hum Neurosci. 2021 Nov 26;15:755025
pubmed: 34899218
Brain Cogn. 2014 Apr;86:82-9
pubmed: 24594658
Br J Radiol. 2019 Sep;92(1101):20181000
pubmed: 31170803
Healthcare (Basel). 2022 Jan 18;10(2):
pubmed: 35206795
J Clin Psychiatry. 2010 Jun;71(6):754-63
pubmed: 20051220
Eur Arch Psychiatry Clin Neurosci. 2011 Apr;261(3):205-11
pubmed: 21103886
J Clin Psychiatry. 2006;67 Suppl 8:7-12
pubmed: 16961424
J Eval Clin Pract. 2012 Feb;18(1):12-8
pubmed: 20698919
Int J Neuropsychopharmacol. 2009 Sep;12(8):1137-47
pubmed: 19580697
J Neurosci. 2002 Jan 15;22(2):389-95
pubmed: 11784783
Riv Psichiatr. 2022 Jul-Aug;57(4):159-164
pubmed: 35856315
J Child Psychol Psychiatry. 2017 Dec;58(12):1290-1300
pubmed: 28714195
J Psychiatr Res. 2014 Jul;54:11-8
pubmed: 24726639
J Atten Disord. 2007 Sep;11(2):150-6
pubmed: 17709815
Clin Neurophysiol. 2015 Apr;126(4):711-20
pubmed: 25097090
J Neurosci. 2012 Jan 18;32(3):841-9
pubmed: 22262882
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Eur Child Adolesc Psychiatry. 2012 Sep;21(9):477-92
pubmed: 22763750
Am J Psychiatry. 2022 Feb;179(2):142-151
pubmed: 34384227
Am J Psychiatry. 2016 Oct 1;173(10):960-966
pubmed: 27690551
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:163-71
pubmed: 24374068
Neuropsychopharmacology. 2003 May;28(5):967-73
pubmed: 12700698
J Clin Psychopharmacol. 2012 Dec;32(6):820-3
pubmed: 23131881
Ann Clin Psychiatry. 2010 May;22(2):94-102
pubmed: 20445836
Postgrad Med. 2014 Sep;126(5):64-81
pubmed: 25295651
Eur Neuropsychopharmacol. 2015 Jan;25(1):85-94
pubmed: 25435084
J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2 Suppl):26S-49S
pubmed: 11833633
Eur Arch Psychiatry Clin Neurosci. 2018 Jun;268(4):337-347
pubmed: 29143159
Nat Genet. 2019 Mar;51(3):577
pubmed: 30696931
J Neural Transm (Vienna). 2016 Aug;123(8):859-65
pubmed: 27091191
Eur Arch Psychiatry Clin Neurosci. 2020 Dec;270(8):1073-1076
pubmed: 31773256
Mol Psychiatry. 2016 Nov;21(11):1643
pubmed: 27502472
Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S35-43
pubmed: 25231833
Arch Gen Psychiatry. 2012 Sep;69(9):952-61
pubmed: 22945622
Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):428-31
pubmed: 16091862
Atten Defic Hyperact Disord. 2017 Mar;9(1):47-65
pubmed: 27866355
Mol Psychiatry. 2018 Jun;23(6):1446-1452
pubmed: 28461697
Prim Care Companion CNS Disord. 2014;16(3):
pubmed: 25317367
Eur J Paediatr Neurol. 2013 Nov;17(6):543-51
pubmed: 23672833
Int J Neuropsychopharmacol. 2015 May 10;18(11):pyv052
pubmed: 25964505
PLoS One. 2012;7(7):e39447
pubmed: 22792176
Curr Mol Med. 2015;15(3):245-52
pubmed: 25817856
J Neurosci. 2010 Oct 20;30(42):14273-83
pubmed: 20962248
Suppl Clin Neurophysiol. 2013;62:19-54
pubmed: 24053030
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
J Psychopharmacol. 2015 Jan;29(1):24-30
pubmed: 25237119
Am J Psychiatry. 2010 Apr;167(4):397-408
pubmed: 20123910
Nucl Med Commun. 2006 Sep;27(9):733-7
pubmed: 16894328
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Eur Psychiatry. 2019 Feb;56:14-34
pubmed: 30453134
Atten Defic Hyperact Disord. 2014 Sep;6(3):153-8
pubmed: 25063344
Neuropsychopharmacology. 2006 Mar;31(3):594-601
pubmed: 15999146
Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5;141B(8):890-4
pubmed: 16917950
BMC Psychiatry. 2021 Jan 11;21(1):26
pubmed: 33430830
Eur Neuropsychopharmacol. 2017 Mar;27(3):239-247
pubmed: 28130000
Psychiatry (Edgmont). 2009 Oct;6(10):21-9
pubmed: 20011465
BMJ Evid Based Med. 2019 Jun;24(3):99-102
pubmed: 30530806
Mol Neurobiol. 2017 Apr;54(3):2189-2200
pubmed: 26941099
Brain. 2018 May 1;141(5):1545-1557
pubmed: 29547978
Eur Child Adolesc Psychiatry. 2019 Nov;28(11):1417-1429
pubmed: 30293121
Expert Rev Neurother. 2016;16(2):131-44
pubmed: 26693882
BMC Med Genomics. 2019 Oct 24;12(1):143
pubmed: 31651322
Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1470-5
pubmed: 18081165
Neuroimage Clin. 2020;26:102206
pubmed: 32062566
Eur Neuropsychopharmacol. 2011 Jul;21(7):508-15
pubmed: 21303732
Brain Behav. 2016 Sep 28;6(12):e00582
pubmed: 28032005
JAMA. 2011 Dec 28;306(24):2673-83
pubmed: 22161946
J Child Adolesc Psychopharmacol. 2005 Apr;15(2):160-79; discussion 157-9
pubmed: 15910202
Harv Rev Psychiatry. 2013 May-Jun;21(3):151-62
pubmed: 23660970
Neurosci Biobehav Rev. 2007;31(7):977-86
pubmed: 17445893
J Child Psychol Psychiatry. 2021 Dec;62(12):1444-1452
pubmed: 33778945
Front Psychol. 2020 Aug 12;11:1991
pubmed: 32903419
Sci Rep. 2020 Nov 2;10(1):18871
pubmed: 33139794
J Atten Disord. 2009 Sep;13(2):175-87
pubmed: 19372500
Ann Nucl Med. 2014 Apr;28(3):220-6
pubmed: 24385293